News | Nanologica

Nanologica rekryterar SVP Sales and Senior Advisor för kromatografi

18 February, 2021

Nanologica har rekryterat Dr. PK Dutta till positionen som SVP Sales and Senior Advisor för affärsområdet kromatografi. Dr. PK Dutta kommer att fokusera på försäljningstillväxt av Nanologicas produkter för kromatografi primärt i USA. För att accelerera försäljningen av kromatografiprodukter, efter den lyckade uppskalningen avNanologicas silikaproduktion till tonskala, har Dr. Dutta rekryterats som SVP Sales and SeniorAdvisor. Rollen innefattar att sätta strategier för tillväxt, samt leda direkt och indirekt försäljningmed fokus på Nordamerika. ” Efter att

Nanologica Recruits SVP Sales and Senior Advisor for Chromatography

18 February, 2021

Nanologica has recruited Dr. PK Dutta as SVP Sales and Senior Advisor for the business area of chromatography. Dr. PK Dutta will focus on sales growth of Nanologica’s chromatography products primarily in the US. To accelerate sales of chromatography products following the successful upscaling of Nanologica’s silica towards ton scale, Dr. Dutta has been recruited as SVP Sales and Senior Advisor. The position includes leading efforts and strategy for market growth in direct and indirect

Nanologica Signs Collaboration Agreement with Zentiva for the use of NLAB Drug Delivery Platforms

27 January, 2021

A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. ” We first met Zentiva

Test Material from Large Scale Production Approved

25 January, 2021

The first batch of test material from the large-scale production of Nanologica AB’s silica has been approved. The quality of the material produced at the CMO Sterling Pharma Solutions in the UK is identical to the material produced at Nanologica’s plant in Södertälje. In December 2020, the first batch of test material from the upscaling to large-scale production of Nanologica’s silica was delivered. Rigorous quality testing of the silica now confirms identical quality to the

Nanologica Engages Scientific Advisors within Inhalation

19 January, 2021

Nanologica AB has engaged two senior scientific advisors within the field of respiratory drug delivery, for the purpose of advancing the NLAB Spiro™ inhalation platform further. Dr. John Pritchard has more than 40 years of experience from the inhalation industry working in various positions, leading and managing global portfolios of technology projects from discovery to market, at for example GlaxoSmithKline, 3M Health Care Ltd and as Head of Respiratory Project Management at AstraZeneca. His vast

Nanologica ändrar datum för publicering av bokslutskommuniké 2020

14 January, 2021

Nanologicas bokslutskommuniké kommer att publiceras fredagen den 26 februari, istället för den 19 februari som tidigare meddelats. Datum för kommande finansiella rapporter: Bokslutskommuniké 2020 26 februari, 2021 Årsredovisning 2020 23 april, 2021 Delårsrapport jan-mar 2021 7 maj, 2021 För ytterligare information, vänligen kontakta: Johanna Johansson, IR

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.